Skip to main content

SQZ Biotechnologies Company (SQZ)

NYSE: SQZ · IEX Real-Time Price · USD
12.15 -0.09 (-0.74%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap339.37M
Revenue (ttm)18.60M
Net Income (ttm)-64.42M
Shares Out27.92M
EPS (ttm)-3.56
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume32,004
Open12.15
Previous Close12.24
Day's Range12.00 - 12.27
52-Week Range11.15 - 36.49
Betan/a
AnalystsStrong Buy
Price Target36.25 (+198.4%)
Est. Earnings DateNov 10, 2021

About SQZ

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develop...

IndustryBiotechnology
IPO DateOct 30, 2020
Employees98
Stock ExchangeNYSE
Ticker SymbolSQZ
Full Company Profile

Financial Performance

In 2020, SQZ's revenue was $21.00 million, an increase of 4.42% compared to the previous year's $20.11 million. Losses were -$50.52 million, 56.9% more than in 2019.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for SQZ stock is "Strong Buy." The 12-month stock price forecast is 36.25, which is an increase of 198.35% from the latest price.

Price Target
$36.25
(198.35% upside)
Analyst Consensus: Strong Buy

News

SQZ Biotechnologies to Present New Data at the Society for Immunotherapy of Cancer Annual Meeting

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it will present updates...

2 weeks ago - Business Wire

SQZ Biotechnologies to Present at the Chardan 5th Annual Genetic Medicines Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be pres...

3 weeks ago - Business Wire

SQZ Biotechnologies to Present at Cantor Global Healthcare Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be pres...

3 weeks ago - Business Wire

SQZ Biotechnologies Announces First Autoimmune Disease Indication for Tolerizing Antigen Carrier (TAC) Platform

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the first clinical tran...

1 month ago - Business Wire

SQZ Biotechnologies to Present at Upcoming Health Care Conferences

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be pres...

1 month ago - Business Wire

SQZ Biotechnologies Reports Second Quarter 2021 Financial Results and Recent Portfolio Updates

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported second quarter 2021 financial...

2 months ago - Business Wire

SQZ Biotechnologies Strengthens Board with Global Commercial and Clinical Development Experience

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the appointments of Bernard ...

3 months ago - Business Wire

SQZ Biotechnologies Presents Regenerative Medicine Data Demonstrating Neuron Generation from Human Pluripotent Stem C...

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented preclinical regenera...

3 months ago - Business Wire

SQZ Biotechnologies' TAC Program Induces Multiple Mechanisms Of Antigen-Specific Tolerance, Animal Study Shows

SQZ Biotechnologies Company (NYSE: SQZ) has announced preclinical results from its Tolerizing Antigen Carrier (TAC) program, showing potential for application in various autoimmune diseases. Data will b...

4 months ago - Benzinga

SQZ Biotechnologies Tolerizing Antigen Carrier (TAC) Program Induces Antigen-Specific Immune Tolerance in Preclinical...

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, is presenting preclinical results fr...

4 months ago - Business Wire

SQZ Biotechnologies Initial First-In-Human Data Demonstrates Investigational Cell Therapy is Safe and Can Stimulate I...

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented initial results from...

4 months ago - Business Wire

SQZ Biotech to Present at Jefferies Virtual Health Care Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will be part...

4 months ago - Business Wire

SQZ Biotechnologies to Present First Clinical Data at the American Society of Clinical Oncology Annual Meeting from O...

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, will present safety and tolerability, manuf...

5 months ago - Business Wire

SQZ Biotechnologies Reports First Quarter 2021 Financial Results and Recent Business Highlights

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today reported financial results for the pe...

5 months ago - Business Wire

SQZ Biotech to Present at BofA Securities 2021 Virtual Health Care Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will be participatin...

5 months ago - Business Wire

SQZ Biotechnologies to Present New Data on Rapid Cell Therapy Manufacturing Capabilities and Advantages in Cell Perfo...

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, announced today that it will present new data on th...

5 months ago - Business Wire

SQZ Biotech Presents Preclinical Data on its mRNA-based enhanced APCs and the Potential of the SQZ APC Platform in KR...

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today shared preclinical data from its next generat...

6 months ago - Business Wire

SQZ Biotech to Participate in April Investor Events

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will be participatin...

6 months ago - Business Wire

SQZ Biotechnologies Reports 2020 Financial Results and Recent Advancements

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today reported full year 2020 financial results and...

7 months ago - Business Wire

SQZ Biotech to Present Preclinical Data on KRAS Tumor Targets and Next Generation SQZ eAPCs at the American Associati...

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that its team will present ...

7 months ago - Business Wire

Should You Buy SQZ Biotechnologies Company (SQZ) Ahead of Earnings?

SQZ Biotechnologies Company (SQZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

7 months ago - Zacks Investment Research

SQZ Biotech to Present at H.C. Wainwright Global Life Sciences Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that Armon Sharei, PhD, chief execut...

7 months ago - Business Wire

Why SQZ Biotechnologies Sank on Friday

The cell-squeezing specialist priced a new stock issue.

8 months ago - The Motley Fool

SQZ Biotechnologies Under Pressure After $60M Equity Raise At 9% Discount

SQZ Biotechnologies Co (NYSE: SQZ) prices its underwritten public offering of 3 million common shares at $20 per share. Underwriters have an option to purchase up to an additional 450,000 shares.

8 months ago - Benzinga

SQZ Biotech Announces Proposed Public Offering of Common Stock

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ) (“SQZ”), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that it has commenc...

8 months ago - Business Wire